Physician profile
Seth Daniel Cahn
NPI 1023147261
$1,336.05
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.41 · 2020: $89.13 · 2021: $295 · 2022: $635 · 2023: $224 · 2024: $53.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $338.83 | 2022 | |
| Abbvie INC. | $265.84 | 2021-2023 | Qulipta, Ubrelvy |
| Biogen, INC. | $176.68 | 2020-2024 | Vumerity, Avonex |
| Lilly USA, LLC | $172.84 | 2021-2022 | |
| Acorda Therapeutics, INC | $60.70 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $46.83 | 2022-2024 | Ajovy, Austedo |
| Janssen Pharmaceuticals, INC | $44.64 | 2022-2023 | Ponvory |
| Biohaven Pharmaceuticals, INC. | $44.62 | 2021 | |
| Argenx US, INC. | $36.98 | 2023 | Vyvgart |
| Biohaven Pharmaceutical Holding Company Ltd. | $26.98 | 2022 | |
| Cala Health, INC. | $21.57 | 2023 | Cala Trio |
| Tanabe Pharma America, INC. | $19.40 | 2024 | |
| Horizon Therapeutics Plc | $19.40 | 2022 | |
| Acadia Pharmaceuticals INC | $16.82 | 2023 | Nuplazid |
| Neuronetics, INC. | $16.70 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $15.60 | 2023 | |
| Sumitomo Pharma America, INC. | $11.62 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Cahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.